ScreenerHero

DCOY Decoy Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · decoytx.com
1.610USD+3.87%Mkt Cap: 1.05M $P/E: 0.13

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (I…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.05M USD
Enterprise Value-7.27M USD
Revenue (TTM)227.63K USD
Gross Profit-1.63M USD
Net Income (TTM)-12.52M USD
Revenue/Share0.64 USD
Last Price1.610 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees11
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.13
P/E (Forward)-0.19
PEG—
EV/EBITDA1.20
EV/Revenue-31.95
P/S4.46
P/B0.19
EPS (TTM)11.90
EPS (Forward)-8.28
52W Range
1.5100% of range55.92
52W High55.92 USD
52W Low1.510 USD
Profitability
Gross Margin0.00%
Oper. Margin-1055.84%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-212.58%
ROA-113.22%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.83M USD
CapEx (TTM)577.00K USD
FCF Margin-224.00%
FCF Yield-48.34%
Net Debt-8.29M USD
Net Debt/EBITDA1.36
Balance Sheet
Debt/Equity—
Current Ratio1.83
Quick Ratio1.77
Book Value/Sh8.12 USD
Cash/Share12.65 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateMar 9, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.000 USD
Upside (mean)+86.3%
Target Range3.000 USD – 3.000 USD
# Analysts1
Ownership
Shares Out.655.18K
Float586.44K
Insiders10.44%
Institutions9.67%
Short Interest
Short Ratio0.4d
Short % Float1.62%
Short % Out.1.61%
Shares Short10.58K
Short (prev mo.)10.68K
Technical
SMA 503.159 (-49.0%)
SMA 2006.224 (-74.1%)
Beta0.64
S&P 52W Chg16.45%
Avg Vol (30d)4.45M
Avg Vol (10d)13.59M
Technical Indicators
RSI (14)30.9
MACD-0.4968
MACD Signal-0.4272
MACD Hist.-0.0695
BB Upper3.694 USD
BB Middle2.478 USD
BB Lower1.263 USD
BB Width98.08%
ATR (14)0.5135 USD
Vol Ratio (20d)0.01x